The first FDA-approved drug for postpartum depression hits the market in June — but it has a $34,000 price tag

  • 📰 CNBC
  • ⏱ Reading Time:
  • 39 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 19%
  • Publisher: 72%

Deutschland Nachrichten Nachrichten

Deutschland Neuesten Nachrichten,Deutschland Schlagzeilen

In June, the first and only medicine approved by the FDA to specifically treat postpartum depression will hit the market. Sage Therapeutics CEO Jeff Jonas says he is hopeful this drug could change the way people think about mental health.

"I'm hoping Zulresso will be the game changer in that people will now see that postpartum is a medical condition that can, and must, be treated," he said.

"The challenge of what we are trying to achieve … is the notion of how can you change the way people think about mental health. If you think about psychiatry in general, it's one of the only areas of medicine where alternative therapies are accepted," he says. If you walked into the doctor's office with diabetes, no one's going to argue if you should have nutritional counseling or insulin. You're going to get the medicine. But in depression, people will say, 'Maybe we don't need medicine. Maybe we should wait."In postpartum depression, this is not your fault," Jonas said. "You have an imbalance, and we can correct it. So the goal for us is to make something that gets people better, gets them back to work.

 

Vielen Dank für Ihren Kommentar.Ihr Kommentar wird nach Prüfung veröffentlicht.

You mean wine-right?

My hope is that women will actually acknowledge that they have postpartum. So many are hesitant to even acknowledge they may be having symptoms due to the stigma that they are like those “mothers in the news.”

Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen:

 /  🏆 12. in DE

Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen